Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

S. Herbst, Roy; Maddox, Anne‐Marie; L. Rothenberg, Mace; J. Small, Eric; H. Rubin, Eric; Baselga, José; Rojo, Federico; Ki Hong, Waun; Swaisland, Helen; D. Averbuch, Steven; Ochs, Judith; LoRusso, Patricia

doi:10.1200/jco.2002.03.038

Public

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Published in Journal of Clinical Oncology • Sep 12, 2002

Authors:

Roy S. Herbst

Anne‐Marie Maddox

Mace L. Rothenberg

Abstract

PURPOSE: To investigate safety, tolerability, dose-related pharmacologic properties, and pharmacodynamics of ZD1839 (gefinitib, Iressa; AstraZeneca Pharmacueticals, Wilmington, DE), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with solid tumor types known to expr...

Subject

Medicine

Rash

Tolerability

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!